DCSIMG

Dundee University set for drugs development centre

The project is being pioneered by researchers at Dundee University. Picture: PA

The project is being pioneered by researchers at Dundee University. Picture: PA

  • by FRANK URQUHART
 

A MAJOR new centre to boost the development of drugs aimed at tackling some of the main diseases affecting people in the developing world is to be created at Dundee University.

The new drug development centre is being established with the aid of £6.5 million in funding from the university, the Wellcome Trust and the Bill and Melinda Gates Foundation, the charity founded by the Microsoft chairman and his wife.

A Dundee University spokesman said: “There is an urgent need for new drugs to treat infectious diseases of the developing world, such as tuberculosis (TB), malaria and African sleeping sickness. However, despite significant efforts in early stage drug discovery, there is a bottleneck when it comes to the lead optimisation stage of molecules targeting these diseases.

“Lead optimisation is a key stage in the drug discovery process, where early leads are improved through cycles of design, synthesis and testing to identify potential drugs which are suitable for testing in a clinical setting. It is a labour intensive process requiring significant laboratory resource over a number of years.”

He explained that, in a bid to break the bottleneck, Professor Paul Wyatt and colleagues at the Drug Discovery Unit (DDU) at the university would be using the £6.5 million in funding to establish a “Centre of Excellence for Lead Optimisation for Diseases of the Developing World” in Dundee.

Professor Wyatt said: “One of the main aims of the Drug Discovery Unit is to make inroads into developing drugs for diseases that affected the developing world. We have the capability through the DDU to help break the bottleneck which occurs at a key stage of the drug discovery process.”

The university spokesman said: “The initial focus will be on TB, the world’s second-leading infectious killer, disproportionately affecting developing countries; in 2010 causing 1.4 million deaths, 8.8 million new infections and 450 thousand drug-resistant TB cases. First-line therapies for TB are old and inadequate, taking six months to cure patients. The long treatment regimen contributes to high treatment default rates that can lead to increased disease transmission, drug resistance, and death.

“The strategy is to identify a portfolio of TB Lead Optimisation projects through the DDU’s involvement with the global HIT-TB consortium and TB Drug Accelerator Program which are working to generate drug leads through their screening programmes. “

Dr Richard Seabrook, head of business development at the Wellcome Trust, said: “We are pleased to be co-funding with the Bill and Melinda Gates Foundation on this exciting UK project, bringing together internationally renowned experts in the biology of infectious diseases with a first-class drug discovery unit to tackle some of the world’s most profound medical needs.”

 

Comments

 
 

Back to the top of the page